Abstract 2597
Background
Cancer holds a huge psychosocial impact. Understanding the diagnosis and treatment gives cancer patients a feeling of autonomy and self-control. The patients’ perspective and expectations on the qualities of a medical oncologist are still poorly known.
Methods
Observational cross-sectional study of cancer patients observed in a Portuguese peripheral hospital in October 2018. When patients knew the primary tumour site, stage of disease and intent of treatment they were considered to have “Full knowledge”. Descriptive statistics and univariate analysis were performed, considering a CI of 95%.
Results
Seventy-two patients were included. Most were men (56.9%), with a median age of 60 years and 65.3% had an ECOG PS of 1. Patients reported feelings of shock (43.0%), sadness (38.9%), fear (34.7%) and courage (33.3%) when they became aware of their oncological diagnosis. About 12.5% of patients needed evaluation by Psychology/Psychiatry on the first 3 months after diagnosis, of which 2/3 had a history of depressive or anxiety disorders. The majority of patients (78%) received the diagnosis in a consultation, 12.5% in the emergency department with 4.2% being informed by their relatives (4.2%). About 90% of patients stated they knew their diagnosis while 5.6% were not sure. Correct identification of the primary tumour site occurred in 87% of patients and 81.9% knew the disease stage. Of those under treatment (n = 58), almost 20% did not understand its intention. About 54% of patients had "full knowledge" of the disease and treatments. There was no significant correlation between socio-demographic and clinical variables and "full knowledge" of the disease, and only age approached the significance level (p = 0.083). Patients mostly valued kindness (62.5%), honesty (55.6%) and knowledge (47.2%) in a medical oncologist.
Conclusions
Despite the majority of patients claiming to be aware of their disease, almost half did not understand the disease stage or treatment intention. Clear communication can contribute to a greater sense of knowledge, autonomy and adaptation to the disease, potentially influencing quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1357 - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab
Presenter: Yuki Sato
Session: Poster Display session 1
Resources:
Abstract